NPI registry status
Active
2026 NPPES data Endocrinology, Diabetes & Metabolism Physician NPI 1740579473 MD
Verify on CMS → Rachel Steinman, MD
Endocrinology, Diabetes & Metabolism Physician in Harrison, New York.
This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers - including 8,078 in Endocrinology, Diabetes & Metabolism Physician, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration, see our methodology.
Federal data, no proprietary rating.
We show these CMS records as-is - no composite score, no star rating, no editorial opinion layered on top.
Prescribing volume
3K
Medicare Part D claims · 481 beneficiaries · Endocrinology, Diabetes & Metabolism Physician avg: 3K
Generic prescribing
45%
generic claims · 47% brand-name · higher generic rates reduce patient out-of-pocket costs
MIPS score
99.2/100
▲ 16 pts above national avg 83.5 · Exceptional
Industry payments
$96.81
4 payments · CMS Open Payments (Sunshine Act)
Source: CMS Medicare Part D Prescriber Public Use File, 2024
What the federal data shows
Rachel Steinman, MD reported a CMS MIPS final score of 99.2/100 - above the 83.5 national average - and filed 2,715 Medicare Part D claims in 2024.
- 99.2/100
- MIPS score · +16 vs avg
- 3K
- Part D claims, 2024
- 45%
- generic prescribing
- Likely
- board-certified (heuristic)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) - no proprietary rating or editorial opinion is applied.
Federal trust snapshot
What official records show about Rachel Steinman, MD
Federal records show an active NPI with both Medicare prescribing volume and a measured CMS quality score — objective registry data, not patient reviews.
- Verified
NPI registry status
Active listing in the CMS National Provider Identifier Registry (NPI 1740579473), first enumerated 04/04/2011.
Source: CMS NPPES
- Reported
Medicare Part D participation
Filed 2,715 Medicare Part D prescription claims in the 2023 CMS public use file — indicates active Medicare prescribing participation.
Source: CMS Part D Prescriber PUF
- Reported
CMS quality reporting (MIPS)
Reported a CMS MIPS final score of 99.2/100 in the Quality Payment Program — a federal quality measure, not a patient review.
Source: CMS Quality Payment Program
- Reported
Board certification signal
Heuristic suggests board-certified status based on ABMS-eligible specialty taxonomy plus active CMS participation signals — not a direct ABMS verification.
- Reported
Industry payment transparency
$96.81 in reported industry payments (4 transfers) in 2024 under the federal Sunshine Act — disclosed transfers of value, not a quality rating.
Source: CMS Open Payments
- State context
State board disciplinary context
New York statewide board action statistics are published annually — these figures describe aggregate state activity, not Rachel Steinman, MD's individual license status. Verify directly with the state medical board.
Source: NYSBPMC annual report 2023
- Not in federal data
Individual sanction lookup
PlainDoctor does not publish per-provider disciplinary determinations. Confirm current license and any individual actions through the state medical board or FSMB verification service.
Source: State medical board / FSMB
This trust snapshot summarizes only what appears in federal CMS/NPPES public records. It is not a composite score, star rating, patient review, or clinical recommendation. PlainDoctor never fabricates reviews or AggregateRating schema.
CMS NPPES provider registry desk
NPI 1740579473 · Endocrinology, Diabetes & Metabolism Physician
NPI-10 · ENUM-MID · TAX-MID · MIPS-ELITE · RX-MID · BOOK-LIGHT · PHOTO-FINISH
- NPI-10 1740579473
- ENUM-MID 2011
- TAX-MID 8K Endocrinology, Diabetes
- MIPS-ELITE 99.2/100
- RX-MID 2,715
- BOOK-LIGHT 813 in New York
- PHOTO-FINISH Anju Agarwal · ±0.0
MIPS final-score neighbourhood
Same-specialty nationwide peers by CMS final score, not geographic proximity
- Steinman · this …
Steinman · this provider
99.2 MIPS pts
- Rajani Gundluru …
Rajani Gundluru
99.2 MIPS pts
- Anju Agarwal · n…
Anju Agarwal
99.2 MIPS pts
- Fabiola D'Ambros…
Fabiola D'Ambrosio
99.2 MIPS pts
- Lance Freeman · …
Lance Freeman
99.2 MIPS pts
What this shows Nearest measured MIPS peers for this NUCC specialty (2023 performance year).
Rachel Steinman, MD's MIPS score vs every measured U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023, the federal quality measure. Clinicians whose score CMS assigned without scoring any category are excluded.
99 ≥ 91st percentile 91% of 454,083 measured providers are in lower value bands
Each bar is a band; taller bars hold more measured providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
The percentile is a conservative whole-score-point band: it counts only measured clinicians in lower score bands. A CMS MIPS metric is not a recommendation or a clinical-quality rating by PlainDoctor. See methodology § corpus placement.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
Where Rachel Steinman, MD sits
This provider among endocrinology, diabetes & metabolism physician peers
Across the 2,341 endocrinology, diabetes & metabolism physician providers who report both Medicare Part D prescribing and a MIPS quality score, Rachel Steinman, MD writes more Part D claims than 55% of them and scores higher on MIPS quality than 92% - placing this provider in the high-volume, high-quality quadrant. Volume reflects patient-panel size and specialty, not quality; the two axes are independent.
Each dot is one endocrinology, diabetes & metabolism physician peer from a representative sample of 60; the gold marker is Rachel Steinman, MD. Source: CMS Medicare Part D Prescriber data and the CMS Merit-based Incentive Payment System, 2023.
✓
Board certification likely (heuristic, not verified)
Rachel Steinman, MD practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting - signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about Rachel Steinman, MD?
High performer (top quartile)Primary specialty
Endocrinology, Diabetes & Metabolism Physician
Medicare Part D claims
2,715 1% vs specialty avg
MIPS final score
99.2/100 15.7 pts vs avg
Specialty distribution in New York
How Endocrinology, Diabetes & Metabolism Physician compares to other specialties among New York providers
Medicare quality performance, MIPS
Rachel Steinman, MD's 2023 MIPS final score plotted against the Endocrinology, Diabetes & Metabolism Physician national average
- MIPS Final Score
- 99.2/100
- vs 83.5 national avg · 2023 performance year
How MIPS and board certification work
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
Practice Address
Provider Details
| NPI | 1740579473 |
|---|---|
| Specialty | Endocrinology, Diabetes & Metabolism Physician |
| Credentials | MD |
| Gender | Female |
| NPI Issued | 04/04/2011 |
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
99.15
Final Score
Measured-score avg: 83.5
99
Promoting Interoperability
Reporting: Group practice
Industry payments received (2024) - CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for Rachel Steinman, MD. Source: openpaymentsdata.cms.gov.
Total received
$97
Largest payer
Novo Nordisk Inc
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias, they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
License & disciplinary context - New York NYSBPMC 2023 annual report
Aggregate state board data only, NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~100K New York medical licensees in 2023 - they are NOT specific to Rachel Steinman, MD. To verify Rachel Steinman, MD's current license status, search the NYSBPMC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
312
Total board actions, New York 2023
Across 302 cases
3.12
Actions per 1,000 licensees
New York statewide rate
probation
Most common action type
89 cases
NYSBPMC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the New York disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Above average
Rachel Steinman, MD - brand share 47.0%
Endocrinology, Diabetes & Metabolism Physician average
47% brand-name claims vs 45% generic, on 2,715 2024 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2024.
2,715
Total Claims
$1.4M
Total Drug Cost
481
Medicare Beneficiaries
Prescribing Breakdown
- 30-Day Fills
- 7,016.3
- Total Day Supply
- 209,471
- Brand vs Generic
- 47% brand / 45% generic
- Brand Drug Cost
- $1.2M
- Generic Drug Cost
- $21K
Patient Demographics
- Average Patient Age
- 75.4 years
- Avg HCC Risk Score
- 1.15
- Gender Split
- 65% female / 35% male
- Age Distribution
- <65: 19, 65-74: 209, 75-84: 197, 85+: 56
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2024. Based on Medicare Part D data only.
What Rachel Steinman, MD prescribes most
Top Medicare Part D drugs by claim count, 2024
- Metformin Hcl Er
Metformin Hcl Er
394 claims
- Levothyroxine Sodium
Levothyroxine Sodium
265 claims
- Synthroid
Synthroid
241 claims
- Mounjaro
Mounjaro
181 claims
- Jardiance 130
Jardiance
130 claims
- Ozempic 101
Ozempic
101 claims
- Nano 2nd Gen Pen N… 97
Nano 2nd Gen Pen Needle
97 claims
- Tresiba Flextouch … 90
Tresiba Flextouch U-100
90 claims
| Drug | Claims |
|---|---|
| Metformin Hcl Er Metformin Hcl | 394 |
| Levothyroxine Sodium | 265 |
| Synthroid Levothyroxine Sodium | 241 |
| Mounjaro Tirzepatide | 181 |
| Jardiance Empagliflozin | 130 |
| Ozempic Semaglutide | 101 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 97 |
| Tresiba Flextouch U-100 Insulin Degludec | 90 |
| Atorvastatin Calcium | 87 |
| Metformin Hcl | 80 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
More Endocrinology, Diabetes & Metabolism Physician in NY →
All providers in New York →
Compare specialties →
Endocrinology, Diabetes & Metabolism Physician Overview
How Rachel Steinman, MD fits within the Endocrinology, Diabetes & Metabolism Physician landscape nationally.
8,078
Endocrinology, Diabetes & Metabolism Physician Providers in US
54
States with Endocrinology, Diabetes & Metabolism Physician
2,739
Avg Claims per Provider
Rachel Steinman, MD's 2,715 claims are below the specialty average of 2,739.
Nationwide Endocrinology, Diabetes & Metabolism Physician peers with similar MIPS or enrollment year
Two federal-record peer sets for Steinman, both outside New York so the neighborhoods are not geographic containment.
Similar MIPS final score
Nearest same-specialty clinicians by CMS MIPS final score (99.2 here).
Same NPPES enumeration year (2011)
Same-specialty clinicians who entered the NPI registry in the same calendar year, outside this state.
Nearby Endocrinology, Diabetes & Metabolism Physician Providers in New York
Other clinicians with the same primary specialty enrolled in New York, drawn from the same CMS NPPES roster as Steinman.
One of 813 Endocrinology, Diabetes & Metabolism Physician providers enrolled in New York, 5 are shown here.
Dr. Zinoviy Abelev
MD
Long Island City, NY
Dr. Jill Abelseth
M.D.
Albany, NY
Dr. Sherley Abraham
M.D.
New York, NY
Dr. Connor Abramowicz
DO
Port Jefferson, NY
Dr. Jennifer Abrams
DO
Brooklyn, NY
Compare Endocrinology, Diabetes & Metabolism Physician nationally: see state-by-state distribution →
Frequently Asked Questions
What is Rachel Steinman, MD's specialty? ▼
Rachel Steinman, MD specializes in Endocrinology, Diabetes & Metabolism Physician and practices in Harrison, New York. Credentials: MD.
How much does Rachel Steinman, MD prescribe under Medicare Part D? ▼
In 2024, Rachel Steinman, MD wrote 2,715 Medicare Part D claims totaling $1.4M in drug costs for 481 beneficiaries.
What is Rachel Steinman, MD's Medicare quality score? ▼
Rachel Steinman, MD has a CMS MIPS Final Score of 99.2/100. The average MIPS Final Score across the 454,083 clinicians with at least one published category score is 83.5; clinicians whose score CMS assigned without scoring any category are excluded from that average. Source: CMS Merit-based Incentive Payment System (MIPS) 2023.
Where is Rachel Steinman, MD located? ▼
Rachel Steinman, MD is located at 600 MAMARONECK AVE, Harrison, NY, 10528. Phone: (914) 723-8100.
What is Rachel Steinman, MD's NPI number? ▼
Rachel Steinman, MD's National Provider Identifier (NPI) is 1740579473, issued on 04/04/2011.
Does Rachel Steinman, MD prescribe more brand-name or generic drugs? ▼
Rachel Steinman, MD's prescribing is 47% brand-name and 45% generic drugs by claim count, with $1.2M in brand drug costs.
How many Endocrinology, Diabetes & Metabolism Physician providers are there in the US? ▼
There are 8,078 Endocrinology, Diabetes & Metabolism Physician providers across 54 states in the US. The average Endocrinology, Diabetes & Metabolism Physician provider writes 2,739 Medicare Part D claims per year.
What drugs does Rachel Steinman, MD prescribe most often? ▼
Based on 2024 Medicare Part D data, Rachel Steinman, MD's most frequently prescribed drugs include Metformin Hcl Er, Levothyroxine Sodium, Synthroid. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does Rachel Steinman, MD accept Medicare? ▼
Rachel Steinman, MD appears in CMS Medicare data with 2,715 Part D claims and 481 Medicare beneficiaries in 2024. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify Rachel Steinman, MD's credentials? ▼
Rachel Steinman, MD's NPI is 1740579473 with credentials MD. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.
Data Sources
View source datasets and methodology notes
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2024). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) - 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of August 2026 (NPPES) / 2024 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology
Every figure on PlainDoctor is rendered directly from the federal CMS NPPES registry, Medicare Part D, MIPS, and Open Payments records, no number is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of August 2026.